Partnerships and co-selling: the complete 2026 guide for healthcare and life sciences in the DACH region

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the DACH region. In this market, DACH buyers reward rigour, documentation, and long-cycle trust — not urgency-led campaigns, so the way you install partnerships and co-selling has to be shaped to that reality from day one.

In 2026, partnerships and co-selling is using another company's distribution to reach buyers you cannot cost-effectively reach yourself. If you are building a B2B revenue engine this year, you cannot afford to treat it as optional.

The reason partnerships and co-selling matters more now than at any point in the last decade is straightforward: one great partner is worth ten marketing hires. That change is compounding month over month, and the teams that installed it early are pulling away.

The mechanics are not complicated. You need a target list narrow enough to be recognisable, an operating rhythm short enough to catch drift within a week, and a north-star metric — for partnerships and co-selling, that is sourced and influenced pipeline from partners — reviewed every Monday.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the DACH region it is compounded by the fact that trust-building cycle length, not intent is what actually gates growth. Partnerships and co-selling is only useful here when it is pointed at both constraints at once.

Most teams that fail at partnerships and co-selling fail the same way: signing MOUs no one operationalises. Every consequence downstream — bad conversion, dead pipeline, burned reputation — traces back to that root cause.

The install curve looks like this. Weeks one and two are diagnosis and instrumentation. Weeks three through six are the first live cycle at deliberately low volume. Weeks seven through twelve are the ramp. By day 90 you should be reading the metric out loud in every leadership meeting.

You do not need a large team to run partnerships and co-selling. You need one owner with authority, one operator with the tools, and a weekly review that is not allowed to slip. Everything else — vendors, seats, decks — is negotiable.

A working partnerships and co-selling function is worth more than the sum of any three point tools you could buy in its place. Once it compounds, you stop asking whether it works and start asking where to put the next dollar. That is the goal.

Concretely for healthcare and life sciences in the DACH region: the healthcare teams that install this get past procurement instead of dying in it, and one properly-run DACH account survives leadership changes and compounds for years. That is the reason it is worth installing partnerships and co-selling deliberately for this market rather than importing a playbook designed for somewhere else.